Stimulation of insulin signaling and inhibition of JNK-AP1 activation protect cells from amyloid-β-induced signaling dysregulation and inflammatory response

Journal of Alzheimer's Disease

Volumn 40, Issue 1, 2014, Pages 105-122

  Bamji Mirza, Michelle ^a,b   Callaghan, Debbie ^a   Najem, Dema ^a,b   Shen, Shanshan ^a,c   Hasim, Mohamed Shaad ^a,b   Yang, Ze ^d   Zhang, Wandong ^a,b,c  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c SOUTHEAST UNIVERSITY   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

Alzheimer's disease; amyloid peptides; inflammatory response insulin signaling; JNK AP1 signaling

Indexed keywords

ACTIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; EARLY GROWTH RESPONSE FACTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INSULIN; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 32; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F1; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENSITOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; INFLAMMATION; INSULIN TREATMENT; LIPID OXIDATION; NEGATIVE FEEDBACK; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ALZHEIMER'S DISEASE; AMYLOID-Β PEPTIDES; INFLAMMATORY RESPONSE INSULIN SIGNALING; JNK-AP1 SIGNALING;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANTHRACENES; BRAIN; CELL LINE, TRANSFORMED; CHEMOKINE CXCL2; CYTOKINES; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INSULIN; MAP KINASE KINASE 4; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84899895504     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131949     Document Type: Article

References (55)

1. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942.
2. Ferreira ST, Klein WL (2011) The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem 96, 529-543.
3. de la Monte SM (2009) Insulin resistance and Alzheimer's disease. BMB Rep 42, 475-481.
4. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An antidiabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 122, 1339-1353.
5. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Tro-janowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
6. Erol A (2009) Unraveling the molecular mechanisms behind the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis 17, 267-276.
7. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP (1997) Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal. J Neu-rochem 69, 273-284.
8. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R (2002) Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22, RC221.
9. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167.
10. Qin W, Jia J (2008) Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42. Eur J Neurosci 27, 2425-2432.
11. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8, 499-509.
12. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113.
13. Aguirre V, Uchida T, Yenush L, Davis R, White MF (2000) The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phos-phorylation of Ser(307). J Biol Chem 275, 9047-9054.
14. Kaneto H (2005) The JNK pathway as a therapeutic target for diabetes. Expert Opin Ther Targets 9, 581-592.
15. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, Romero IA, Weksler B, Stanimirovic DB, Zhang W (2009) Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 34, 95-106.
16. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH (2009) Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelialCCR5expression andpromotes T cells crossing the blood-brain barrier. J Immunol 182, 5778-5788.
17. Du H, Li P, Wang J, Qing X, Li W (2012) The interaction of amyloid beta and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. Cell Mol Neurobiol 32, 141-147.
18. Tu YF, Tsai YS, Wang LW, Wu HC, Huang CC, Ho CJ (2011) Overweight worsens apoptosis, neuroinflammation and blood-brain barrier damage after hypoxic ischemia in neonatal brain through JNK hyperactivation. J Neuroinflammation 8, 40.
19. Pang T, Wang J, Benicky J, Sanchez-Lemus E, Saavedra JM (2012) Telmisartan directly ameliorates the neuronal inflammatory response to IL-1beta partly through the JNK/c-Jun and NADPH oxidase pathways. J Neuroinflammation 9, 102.
20. Leow-Dyke S, Allen C, Denes A, Nilsson O, Maysami S, Bowie AG, Rothwell NJ, Pinteaux E (2012) Neuronal tolllike receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro. J Neuroinflammation 9, 230.
21. Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, Pei K, Walker D, Lue LF, Stanimirovic D, Zhang W (2009) ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J Neurosci 29, 5463-5475.
22. Exalto LG, Whitmer RA, Kappele LJ, Biessels GJ (2012) An update on type 2 diabetes, vascular dementia and Alzheimer's disease. Exp Gerontol 47, 858-864.
23. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19, 1872-1874.
24. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57.
25. Karin M, Liu Z, Zandi E (1997) AP-1 function and regulation. Curr Opin Cell Biol 9, 240-246.
26. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. J Neurosci 29, 9078-9089.
27. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neuro-biol Dis 30, 107-120.
28. Noshita T, Murayama N, Oka T, Ogino R, Nakamura S, Inoue T (2012) Effect of bFGF on neuronal damage induced by sequential treatment of amyloid beta and excitatory amino acid in vitro and in vivo. Eur J Pharmacol 695, 76-82.
29. Jarvis K, Assis-Nascimento P, Mudd LM, Montague JR (2007) Beta-amyloid toxicity and reversal in embryonic rat septal neurons. Neurosci Lett 423, 184-188.
30. Feng C, Zhang C, Shao X, Liu Q, Qian Y, Feng L, Chen J, Zha Y, Zhang Q, Jiang X (2012) Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of beta-amyloid and ibotenic acid into the bilateral hippocampus. Int J Pharm 423, 226-234.
31. Verdoliva A, Rivieccio V, Rossi M (2010) Simplified beta-amyloid peptides for safer Alzheimer's vaccines development. Hum Vaccin 6, 936-947.
32. Haglund M, Kalaria R, Slade JY, Englund E (2006) Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. Acta Neuropathol 111, 430-435.
33. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, Suzuki N, Younkin SG (1995) Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270, 7013-7016.
34. Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: An update. J Neural Transm 109, 813-836.
35. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA (2010) Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 14, 1101-1112.
36. Kania KD, Wijesuriya HC, Hladky SB, Barrand MA (2011) Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells. Brain Res 1418, 1-11.
37. Viatour P, Merville MP, Bours V, Chariot A (2005) Phospho-rylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation. Trends Biochem Sci 30, 43-52.
38. Dick FA, Dyson N (2003) pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol Cell 12, 639-649.
39. Xia MQ, Hyman BT (1999) Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 5, 32-41.
40. Forloni G, Mangiarotti F, Angeretti N, Lucca E, De Simoni MG (1997) Beta-amyloid fragment potentiates IL-6 and TNF-alpha secretion by LPS in astrocytes but not in microglia. Cytokine 9, 759-762.
41. Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: Inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal 2012, 756357.
42. Vom Berg J, Prokop S, Miller KR, Obst J, Kalin RE, Lopategui-Cabezas I, Wegner A, Mair F, Schipke CG, Peters O, Winter Y, Becher B, Heppner FL (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 18, 1812-1819.
43. Cho KS, Park SH, Joo SH, Kim SH, Shin CY (2010) The effects of IL-32 on the inflammatory activation of cultured rat primary astrocytes. Biochem Biophys Res Commun 402, 48-53.
44. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ (2010) Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 119, 669-678.
45. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S (2005) Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 62, 1539-1544.
46. Dandona P (2002) Endothelium, inflammation, and diabetes. Curr Diab Rep 2, 311-315.
47. Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B (2012) Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol Rev 64, 1004-1026.
48. Mehan S, Meena H, Sharma D, Sankhla R (2011) JNK: A stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J Mol Neurosci 43, 376-390.
49. Han L, Yin K, Zhang S, Wu Z, Wang C, Zhang Q, Pan J, Chen B, Li J, Tan R, Xu Y (2013) Dalesconols B inhibits lipopolysaccharide induced inflammation and suppresses NF-kappaB and p38/JNK activation in microglial cells. Neurochem Int 62, 913-921.
50. Bain J, McLauchlan H, Elliott M, Cohen P (2003) The specificities ofprotein kinase inhibitors:Anupdate.Biochem J371, 199-204.
51. Lu Y, Zeft AS, Riegel AT (1993) Cloning and expression of a novelhuman DNA binding protein, PO-GA.Biochem Biophys Res Commun 193, 779-786.
52. Thiele DJ (1992) Metal-regulated transcription in eukaryotes. Nucleic Acids Res 20, 1183-1191.
53. Petronini PG, Alfieri R, Campanini C, Borghetti AF (1995) Effect of an alkaline shift on induction of the heat shock response in human fibroblasts. J Cell Physiol 162, 322-329.
54. Costa RH, Grayson DR, Xanthopoulos KG, Darnell JE Jr (1988) A liver-specific DNA-binding protein recognizes multiple nucleotide sites in regulatory regions of transthyretin, alpha 1-antitrypsin, albumin, and simian virus 40 genes. Proc Natl Acad Sci U S A 85, 3840-3844.
55. Scott GK, Daniel JC, Xiong X, Maki RA, Kabat D, Benz CC (1994) Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells. J Biol Chem 269, 19848-19858.